Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy
A Randomized, Multicenter, Open Phase III Study Comparing the Postoperative Use of Zoledronic Acid Versus no Treatment in Patients With Histological Tumor Residuals After Preoperative Anthracycline and Taxane Containing Chemotherapy for Primary Breast Cancer
Sponsor: Austrian Breast & Colorectal Cancer Study Group
Listed as NCT00512993, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by Austrian Breast & Colorectal Cancer Study Group, it has been updated 7 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Dec 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Austrian Breast & Colorectal Cancer Study Group
- GBG Forschungs GmbH
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalen, Germany, Berlin, Germany, Bernau bei Berlin, Germany, Bielefeld, Germany, Bochum, Germany, Bremen, Germany, Böblingen, Germany, Celle, Germany, Chemnitz, Germany, Coesfeld, Germany and 70 more location s